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Rates of obesity pharmacotherapy use, bariatric surgery and intensive behavioural
counselling have been extremely low.
Objectives
The primary objective of this study was to survey healthcare provider beliefs, practice
and knowledge regarding obesity management.
Methods
Primary care physicians (PCPs), OB-GYN physicians and nurse practitioners (NPs)
responded to a web-based survey related to drug therapy practice, bariatric surgery
referral and reimbursement coding practice.
Results
Rates of reported use of obesity pharmacotherapy appear to be increasing among PCPs,
which is likely related to the approval of four new obesity pharmacotherapy agents since
2012. Rates of pharmacotherapy use among OB-GYNs and NPs appear much lower.
Similarly, few PCPs are averse to recommending bariatric surgery, but aversion among
OB-GYNs and NPs is significantly higher.
Conclusion
Together, these observations suggest that OB-GYN and NP populations are important
targets for education about obesity management. Very few PCPs, OB-GYNs or NPs
use behavioural counselling coding for obesity. Better understanding of why this benefit
is not being fully used could inform outreach to improve counselling rates.
Keywords: Bariatric surgery referral, CPT coding, obesity counselling, obesity
pharmacotherapy.
Introduction
Obesity medicine specialists typically use a stepped
care approach of increasing therapeutic intensity, aligned
with severity, including intensive behavioural therapy
(IBT), pharmacotherapy and bariatric surgery (1). IBT is
the first recommended treatment option, typically
modelled after the United States Preventive Services
Task Force (USPSTF) guidelines. USPSTF recommends
intensive, multicomponent behavioural interventions for
patients with body mass index (BMI) over 30 kgm2 (2).
High intensity behavioural interventions include nutrition
and behaviour modification education, goal setting,
addressing barriers to change, self-monitoring and
weight maintenance strategies, delivered by individual
and/or group counselling over a 12-month period.
Because the prevalence of obesity in the Medicare
population was 36% between 2011 and 2014, there is
clearly a need for these services (3). Despite coverage
by Medicare, utilization of the IBT benefit is extremely
low. Approximately 0.5% of eligible Medicare beneficia-
ries used the IBT service in 2013. Among those patients
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utilizing the benefit, most attended fewer sessions than
recommended by USPSTF (4).
In addition to the IBT recommendations from USPSTF,
the 2013 AHA/ACC/TOS Guideline for the Management
of Overweight and Obesity in Adults guides providers to
intensify treatment with pharmacotherapy and bariatric
surgery if needed. Pharmacotherapy for obesity is
indicated for individuals with a BMI greater than
30 kgm2 or BMI greater than 27 kgm2 with at least one
obesity-associated comorbid condition (5). In 2012,
35% of US adults had a BMI that met these criteria (6).
Most medications work by diminishing appetite.
Combining pharmacotherapy and IBT results in greater
weight loss than either alone.(7) Six Food and Drug
Administration-approved pharmacotherapy options
account for nearly all obesity medication prescriptions
written in the USA: phentermine, orlistate, lorcaserin,
phentermine/topiramate ER, naltrexone/bupropion SR
and liraglutide 3.0mg. Despite the efficacy of and need
for this treatment, only 0.7–2% of eligible patients
receives a prescription for an obesity medication (8,9).
Bariatric surgery is a third option recommended by the
2013 guidelines for adults with a BMI greater than
40 kgm2, or a BMI greater than 35 kgm2 with at least
one comorbid condition, and who have not responded
to behavioural treatment (with or without pharmacother-
apy) (10). The prevalence of severe obesity reached
6.4% in 2011–2012 (6). Bariatric surgery generally
achieves weight loss while improving or resolving a
variety of comorbid conditions. The rate of bariatric
surgery per 100,000 population has plateaued since
2009, with 179,000 operations performed in 2013 (11).
Similar to IBT and pharmacotherapy utilization, the
plateau in bariatric procedures seems paradoxical in the
face of the prevalence of severe obesity.
Previous research has focused on provider utilization
of counselling, with relatively little research on the
frequency with which providers recommend pharmaco-
therapy or refer for bariatric surgery. However, the
available research suggests that while providers may
have positive impressions of the effectiveness of bariatric
surgery, few are willing to refer patients for surgery (12).
Many of these studies focus only on primary care
physicians, but not other types of healthcare providers
(HCP) like nurse practitioners (NPs) and OB-GYNs,
many of whom provide primary services in their
practices. We have included these provider types
because primary care NPs deliver similar services and
spend their time in nearly identical ways to primary care
physicians, and the association of obesity with compli-
cations in pregnancy and infertility treatment point to
the role of OB-GYNs in addressing the obesity epidemic
(13,14).
We compared the utilization of IBT, pharmacotherapy
and referral for bariatric surgery to current treatment
recommendations for counselling, pharmacotherapy and
bariatric surgery by assessing the beliefs, practices and
knowledge of a range of HCPs (5).
Methods
Data were collected in June 2015 using DocStyles, an
Internet panel survey. George Washington University
researchers in concert with Porter Novelli, a public
relations firm, designed eight survey questions. The
national sample was randomly selected using SERMO’S
Global Medical Panel, which includes over 330,000
medical professionals in the USA. The sample included
1,000 primary care physicians (465 family physicians
and 535 internists), 250 OB-GYNs and 251 NPs.
Participants were paid $35–$80 upon completing the
survey. Participants were screened to include only those
who practise in the USA, actively see patients, work in
an individual, group or hospital practice and have been
practising for at least 3 years.
The survey contained a total of 131 questions (eight of
which are reported here) related to demographics
(gender, race, age, height and weight), medical practice
(income of patient population, setting, years in practice
and type of practice), and practices concerning obesity
treatment. Self-reported height and weight were used to
calculate BMI (kgm2) of the respondents. Participants
were asked about their practices regarding drug therapy,
bariatric surgery recommendation and reimbursement
coding.
Drug therapy practices were assessed through the
question, ‘What is typically your minimum requirement
for prescribing drug therapy for obesity treatment?’
Participants could select one of the following: ‘I do not
prescribe drug therapy for obesity’; ‘BMI greater than or
equal to 30 kgm2 with a comorbid condition’; ‘BMI greater
than or equal to 30 kgm2; BMI greater than or equal to
35 kgm2 with a comorbid condition’; ‘BMI greater than
or equal to 35 kgm2, BMI greater than or equal to
40 kgm2’.
Bariatric surgery recommendation practice was
assessed through the question, ‘What is typically your
minimum requirement for recommending bariatric
surgery?’ Participants could select one of the following:
‘I would not recommend bariatric surgery’; ‘BMI greater
than or equal to 35 kgm2 with a comorbid condition’;
‘BMI greater than or equal to 35 kgm2; BMI greater than
or equal to 40 kgm2 with a comorbid condition’; ‘BMI
greater than or equal to 40 kgm2; BMI greater than or
equal to 45 kgm2’.
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Reimbursement coding practice was assessed through
the question, ‘What Current Procedural Terminology
(CPT) code do you use when dedicating an office visit to
weight management or obesity counselling?’ Participants
could select one of the following: ‘General office visit
(99213)’; ‘Preventive service visit (99391)’; ‘Wellness office
visit (G0439)’; ‘Behavioural counselling (G0477)’; ‘Medical
nutrition therapy (97803)’; and ‘I do not code for an
obesity visit’.
Statistical analysis was performed using STATA
software (StataCorp. 2015. Stata Statistical Software:
Release 14. College Station, TX: StataCorp LP).
Chi-squared tests and analysis of variance tests
assessed differences in provider characteristics by
specialty.
Results
The response rate for the survey was 77%, and a total of
1,501 providers participated. Eighty-nine per cent of
PCPs 72% of OB-GYN, and 52% of NPs responded.
Table 1 describes their demographic information. The
majority of participants (62%) were White men, except
among NPS (13%). The average age was 46.6 years
(M=46.4, SD=10.30), although OB-GYN were slightly
older (M=49.4, SD=10.35). Over two-thirds of respon-
dents worked in a group outpatient practice (66%) and
the average length of practice was 16 years (M=16,
SD=8.75). The prevalence of obesity in each group was
10%, 8% and 14% among PCPs, OB-GYNs and NPs,
respectively.
Provider practices by provider type
Table 2 describes provider practices concerning drug
therapy, bariatric surgery and use of Current Procedural
Terminology (CPT) codes. Half of NPs and almost half of
OB-GYN do not prescribe drug therapy for obesity. PCPs
consider BMI greater than or equal to 30 kgm2 with a
comorbid condition the minimum requirement to
prescribe drug therapy for obesity treatment. In each
answer choice, PCPs are consistently more likely than
other specialties to prescribe medications (P<0.001).
Nearly one-third of both PCPs and OB-GYN consider a
BMI greater than 35 kgm2 with a comorbidity to be the
minimum requirement for recommending bariatric
surgery. Almost one-third of NPs would not recommend
bariatric surgery, although 23% of NPs consider a BMI
greater than 35 kgm2 with a comorbidity to be a
minimum requirement for surgical recommendation.
PCPs are the least likely to report never recommending
bariatric surgery (5%) followed by OB-GYN (14%)
(P<0.001).
Many providers code office visits dedicated to obe-
sity counselling as a general office visit (42%), although
approximately one-third of OB-GYN and NPs do not
code for obesity visits. Rates of coding are highest for
PCPs (84%) (P< 0.01). Medical nutrition therapy,
behavioural counselling, wellness office visit and
preventive service visit are all coded less than 10% of
the time. These trends were seen across specialties as
well, with PCPs reporting higher coding rates in all but
one category (P< 0.01).
Table 1 Demographics
Total PCPs OB-GYNs NPs
Age
Mean (standard deviation) 46.55 (10.30) 45.93 (10.17) 49.35 (10.35) 46.28 (10.615)
Gender
Male 62% 74% 59% 13%
Female 38% 22% 41% 87%
Race
White 66% 59% 73% 88%
Black or African American 3% 2% 3% 5%
Asian 23% 30% 16% 4%
Two or more races 3% 3% 4% 3%
Other race 5% 6% 3% 1%
Work setting
Group outpatient practice 66% 66% 70% 56%
Individual outpatient practice 20% 20% 24% 19%
Inpatient practice 15% 14% 6% 25%
Years of practice
Mean (standard deviation) 15.91 (8.76) 15.42 (8.48) 18.59 (9.00) 14.52 (9.39)
PCP, primary care physician; NP, nurse practitioner.
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Provider practices by gender
Men were more likely to code for an obesity visit and their
highest rate of coding was for general office visits
(P< 0.001). Men are more likely than women to prescribe
drugs overall (75% vs. 61%) and across each answer
choice (P< 0.001) (Table 3). Both men and women are
most likely to indicate that a BMI greater than or equal
to 30 kgm2 with a comorbid condition is the minimum
requirement for prescription. Men are more likely than
women to recommend surgery (94% vs. 82%)
(P< 0.001). Although men were more likely to recom-
mend surgery in each BMI category as well as overall,
the most frequent response for men was BMI greater than
or equal to 40 kgm2 (31%) whereas the most frequent
response for women was a BMI greater than or equal to
25 kgm2 with a comorbid condition.
Provider practices by provider obesity
Prevalence of obesity among providers was 10%. Rates
of prescribing drug therapy were lowest for providers
who had obesity (58%) and highest for providers who
were underweight (79%) (P<0.001) (Table 4). Only 21%
of underweight providers reported never prescribing drug
therapy, compared with 42% of providers with obesity
(P< 0.001). Sixty-nine per cent of providers with a healthy
weight and 74% of overweight providers reported that
they prescribed drug therapy. Providers with obesity were
less likely to recommend bariatric surgery than their
overweight and healthy weight peers (16% compared
with 8% and 12%, respectively) (P< 0.001). Underweight
Table 3 Gender differences in obesity practice
Men Women
What is typically your minimum requirement for prescribing drug
therapy for obesity treatment?***
BMI> 30 19% 16%
BMI> 30 with a comorbid condition 25% 20%
BMI> 35 8% 6%
BMI> 35 with a comorbid condition 17% 13%
BMI> 40 4% 4%
None of the above 2% 2%
I do not prescribe drug therapy for obesity 25% 39%
What is typically your minimum requirement for recommending
bariatric surgery?***
BMI> 35 with a comorbid condition 29% 32%
BMI> 40 18% 13%
BMI> 40 with a comorbid condition 31% 23%
BMI> 45 6% 4%
BMI> 45 with a comorbid condition 10% 10%
I would not recommend bariatric surgery 6% 18%
What CPT code do you use when dedicating an office visit to weight
management or obesity counselling?**
General office visit (e.g. 99213) 45% 38%
Wellness office visit (e.g. G0439) 10% 9%
Behavioural counselling (e.g. G0447) 9% 8%
Medical nutrition therapy (e.g. 97803) 6% 5%
Preventive service visit (e.g. 99391) 12% 12%
I do not code for an obesity visit 19% 28%




BMI, body mass index; CPT, Current Procedural Terminology.
Table 4 Influence of provider BMI on drug prescription and bariatric
surgery recommendation
BMI category
P valueUnderweight Healthy Overweight Obesity
Prescribe drug therapy
Yes 79% 69% 74% 58% <0.01
No 21% 31% 26% 42%
BMI, body mass index.
Table 2 Practices concerning obesity treatment: drug therapy,
bariatric surgery and CPT coding
Total PCPs OB-GYNs NPs
What is typically your minimum requirement for prescribing drug
therapy for obesity treatment?***
BMI> 30 17% 19% 18% 11%
BMI> 30 with a comorbid
condition
23% 26% 15% 18%
BMI> 35 7% 8% 6% 5%
BMI> 35 with a comorbid
condition
16% 18% 9% 10%
BMI> 40 4% 5% 4% 3%
None of the above 2% 2% 1% 3%
I do not prescribe drug
therapy for obesity
31% 22% 47% 50%
What is typically your minimum requirement for recommending
bariatric surgery?***
BMI> 35 with a comorbid
condition
30% 32% 29% 23%
BMI> 40 16% 18% 14% 8%
BMI> 40 with a comorbid
condition
28% 30% 25% 23%
BMI> 45 5% 4% 10% 3%
BMI> 45 with a comorbid
condition
10% 10% 9% 13%
I would not recommend
bariatric surgery
11% 5% 14% 30%




BMI, body mass index; CPT, Current Procedural Terminology; PCP,
primary care physician; NP, nurse practitioner.
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providers were the most likely to report recommending
surgery (100%) (P<0.001).
Discussion
This article adds to the literature about HCP practices
related to obesity treatment by examining current HCP
practices in counselling, prescription for medication and
referral for surgery. In addition to assessing HCP attitudes
overall, we evaluated differences between PCPs,
OB-GYNs and NPs. Rates of reported use of obesity
pharmacotherapy appear to be increasing among PCPs,
which is likely related to the approval of four new obesity
pharmacotherapy agents since 2012. NPs and OB-GYNs
are less likely than PCPs to prescribe obesity
medications. The low rate of utilization among NPs might
be explained by widely varying scope of practice laws
influencing prescriptive authority at the state level;
however, it is unclear why OB-GYN rates are similarly
low. A 2006 study found only 35% of OB-GYNs surveyed
had ever prescribed a weight loss medication to their
patients with obesity. Results suggest that prescription
rates may be increasing within this specialty (15). As the
BMI category of the providers increased, their likelihood
to prescribe drug therapy decreased significantly. This
finding aligns with research that suggests providers with
a healthy BMI are more likely to engage in weight loss
discussions and provide recommended obesity care to
their patients (16).
Among those providers who prescribe medications for
obesity, respondents most frequently indicated their
minimum threshold for prescribing was a BMI greater
than 30 kgm2 or BMI greater than 30 kgm2 with a
comorbid condition. This threshold is close to the current
recommendation (30 kgm2 or 27 kgm2 with a comorbid
condition), which suggests that those who do prescribe
(40% of respondents) are likely following recommenda-
tions when they do so.(5) However, 31% of respondents
do not prescribe obesity drugs at all, and 29% prescribe
at higher thresholds than recommended. That 60% of
respondents report prescribing behaviour misaligned with
the clinical guidelines provides evidence of significant
gaps in knowledge or disregard for the standard of care
in obesity pharmacotherapy treatment.
Few PCPs are averse to recommending bariatric
surgery, but aversion among OB-GYNs and NPs is
significantly greater. While both groups are less likely than
PCPs to make surgical referrals, there is a wider gap
between the two specialties than with pharmacotherapy;
rates of non-referral are almost twice as high among
NPs compared with OB-GYNs. Still, these results, and
the lower prescribing practices, suggest that further
education about obesity management is warranted for
OB-GYNs and NPs.
Among providers who refer for bariatric surgery,
responders most frequently indicated 35 kgm2 with a
comorbid condition and 40 kgm2 with a comorbid
condition as their minimum threshold for referral. This
practice is consistent to the current recommendation
(40 kgm2 or 35 kgm2 with a comorbid condition),
indicating that most of the providers discussing
bariatric surgery with their patients are following
recommendations when they do so.(5) Rates of referral
are much higher than rates of prescribing drug
therapy: 89% of providers indicated some level of
referral for bariatric surgery. There were no significant
differences in likelihood for referral among providers with
different BMIs, although similar to pharmacotherapy, the
trend suggests a decreasing rate of referral with
increased BMI.
Primary care physicians tend to utilize CPT codes
related to obesity more than OB-GYNs or NPs (85%
compared with 68% and 60%, respectively), again
indicating education on obesity counselling is needed
for these two provider groups in particular. As has been
previously reported, utilization of IBT is low, despite
Medicare’s decision to cover IBT in 2011.(17,18) Better
understanding of why this benefit is not better utilized will
inform outreach to improve counselling rates.
Female respondents were less likely to prescribe
pharmacotherapy, refer for bariatric surgery or report
counselling on obesity at all. There is limited research
on gender differences in obesity management among
providers.
While DocStyles provides a large, national sample,
these data may not accurately reflect the views of HCPs
in the USA. Participation in the survey is voluntary and
awarded with an honorarium, likely creating self-selection
bias. Quotas for specialty, race/ethnicity and age may
have excluded the perspectives of other providers.
DocStyles has not been tested for reliability or validity.
Because all data are self-reported, the results may be
skewed towards more desirable answers, rather than
actual attitudes or practice in obesity counselling.
Additionally, many obesity specialists are often
categorized and counted as primary care physicians.
These results may overestimate the true counselling,
prescribing, referrals that occur in true primary care
practitioners who do not practice obesity medicine
full-time. The clinical guidelines used to compare
provider practice with the standard of care were
developed in 2013 (5). Given their relative recent
introduction, it is possible these guidelines have not
yet completely penetrated into the specialties
surveyed here.
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Conclusion
Obesity continues to have significant and devastating
effects on the health of adults in the USA. HCPs are
now presented with the challenge of addressing this
disease with their patients. Our study provides a clearer
picture of the current attitudes and practices of a range
of providers, including PCPs, OB-GYNs and NPs. PCPs
tend to have higher rates of prescription for pharmaco-
therapy, referral for bariatric surgery and utilization of
CPT codes for obesity counselling. However, a sizable
portion of PCPs still are not prescribing, referring or
counselling patients with obesity. PCPs, OB-GYNs and
NPs have significant room for improvement in these three
areas. Provider training and education is needed to
prepare both physicians and NPs to deliver appropriate
care to their patients with obesity. Further research can
help determine how providers can best utilize their own
specialty to engage in obesity treatment and better
address obesity overall.
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